The information in this prospectus is not complete and may be changed. We may not sell the securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting any offer to buy these securities in any jurisdiction where such offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED MARCH 26, 2021
PROSPECTUS
Up to US$200,000,000 of
Class A Ordinary Shares
Class A Ordinary Shares in the Form of American Depositary Shares
Preferred Shares
Debt Securities
Warrants
Rights
and
Units
![LOGO](https://capedge.com/proxy/F-3/0001193125-21-096667/g133779g36y56.jpg)
LIZHI INC.
We may, from time to time, in one or more offerings, offer and sell up to US$200,000,000 of any combination, together or separately, of our Class A ordinary shares, par value US$0.0001 per share, Class A ordinary shares in the form of American Depositary Shares, or ADSs, preferred shares, debt securities, warrants, rights, and units, or any combination thereof as described in this prospectus. Each ADS represents 20 Class A ordinary shares. In this prospectus, references to the term “securities” refers collectively to our Class A ordinary shares, Class A ordinary shares in the form of ADSs, preferred shares, debt securities, warrants, rights, and units. The prospectus supplement for each offering of securities will describe in detail the plan of distribution for that offering. For general information about the distribution of the securities offered, please see “Plan of Distribution” in this prospectus.
This prospectus provides a general description of the securities we may offer. We will provide the specific terms of the securities offered in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may add, update, or change information contained in this prospectus. You should read carefully this prospectus, the applicable prospectus supplement, and any related free writing prospectus, as well as the documents incorporated or deemed to be incorporated by reference, before you invest in any of our securities. This prospectus may not be used to offer or sell any securities unless accompanied by the applicable prospectus supplement.
Our ADSs are listed on The Nasdaq Global Market, or Nasdaq, under the symbol “LIZI.” On March 25, 2021, the last reported sale price of the ADSs on NASDAQ was US$8.00 per ADS. On December 31, 2020, the last reported sale price of our ADSs was US$3.88 per ADS, and during the year ended December 31, 2020, the high and low closing prices were US$11.63 and US$1.96 per ADS, respectively. We have recently experienced price volatility in our stock. See related risk factors in our most recent annual report on Form 20-F.
The aggregate market value of our outstanding ordinary shares held by non-affiliates, or public float, as of March 26, 2021, was approximately US$269 million, which was calculated based on 671,840,030 Class A ordinary shares and 0 Class B ordinary shares held by non-affiliates and the per ADS price of US$8.00 (which equals US$0.40 per Class A ordinary share), which was the closing price of our ADS on Nasdaq on March 25, 2021. During the 12 calendar months prior to and including the date of this prospectus, we have not offered or sold any securities pursuant to General Instruction I.B.5 of Form F-3.
Investing in our securities involves risks. See “Risk Factors” beginning on page 5 of this prospectus and risk factors set forth in our most recent annual report on Form 20-F, in other reports incorporated herein by reference, and in an applicable prospectus supplement under the heading “Risk Factors.”
We may offer and sell the securities from time to time at fixed prices, at market prices, or at negotiated prices, to or through underwriters, to other purchasers, through agents, or through a combination of these methods. If any underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable commissions or discounts will be set forth in a prospectus supplement. The offering price of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. See “Plan of Distribution” elsewhere in this prospectus for a more complete description of the ways in which the securities may be sold.
Neither the U.S. Securities and Exchange Commission nor any state securities commission nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is [ ], 2021